Clinical outcomes of coronavirus disease 2019 (COVID-19) in cancer patients with prior exposure to immune checkpoint inhibitors

作     者：Qiuji Wu Qian Chu Hongyan Zhang Bin Yang Xudong He Yahua Zhong Xianglin Yuan Melvin L.K.Chua Conghua Xie 

作者机构：Department of Radiation and Medical OncologyZhongnan Hospital of Wuhan UniversityWuhanHubei 430071P.R.China Hubei Key Laboratory of Tumor Biological BehaviorsZhongnan Hospital ofWuhan UniversityWuhanHubei 430071P.R.China Hubei Cancer Clinical Study CenterZhongnan Hospital ofWuhan UniversityWuhanHubei 430071P.R.China Department of OncologyTongji HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhanHubei 430030P.R.China Department of Medical OncologyHubei Cancer HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhanHubei 430079P.R.China Department of GastroenterologyDongfeng HospitalHubei University of MedicineShiyanHubei 442000P.R.China Divisions of Radiation Oncology and Medical SciencesNational Cancer Centre SingaporeSingapore 169610Singapore Oncology Academic ProgrammeDuke-NUS Medical SchoolSingapore 169857Singapore 

出 版 物：《Cancer Communications》 (癌症通讯（英文）)

年 卷 期：2020年第40卷第8期

页      面：374-379页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：supported by the National Medical Research Council Clinician-scientist award(NMRC/CSA/0027/2018) the Health Commission of Hubei Province Scientific Research Project(WJ2019H002) Health Commission of Hubei Province Medical Leading Talent Project,Fundamental Research Funds for the Central Universities(2042018kf1037,2042019kf0329) Medical Science Advancement Program(Basic Medical Sciences)of Wuhan University(TFJC2018005) Zhongnan Hospital of Wuhan University Science,Technology and Innovation Seed Fund(znpy2017049,znpy2018070) 

主　　题：patients cancer immune 

摘      要：Dear Editor,The coronavirus disease 2019(COVID-19)pandemic has affected over 6,000,000 people globally[1].Patients with COVID-19 manifest with symptoms of fever,dry cough,dyspnea,and present with radiological changes that are consistent with atypical pneumonia[2].Pathogenetic mechanisms for these abnormalities involve the systemic immune response that is associated with the hyperactivation of peripheral CD8+and CD4+T cells,and a cytokine storm[3].Globally,the reported prevalence of patients with COVID-19 and cancer ranges from 0.5%to 6.0%in the different case series[4].